Medico Remedies Ltd. (MEDICO) AI Stock Analysis

• Market Cap: ₹4.00B
• Dividend Yield: N/A
• Average Volume (3M): 41.76K
• Price to Earnings (P/E): 39.7
• Beta (1Y): 0.14
• Revenue Growth: 4.15%
• EPS Growth: 21.74%
• Country: IN
• Employees: 193
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 82,984,000
• 10 Day Avg. Volume: 74,580
• 30 Day Avg. Volume: 41,759
• PEG Ratio: 1.99
• Price to Book (P/B): 7.06
• Price to Sales (P/S): 2.92
• P/FCF Ratio: 258.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹47.00
• Price Target Upside: -2.06% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: ₹47.00 ▼(-2.06% Downside)

Medico Remedies Ltd. demonstrates strong financial performance with robust revenue growth and profitability. However, technical indicators suggest mixed momentum, and the valuation appears high, which could limit upside potential. The absence of earnings call and corporate events data limits additional insights.

Medico Remedies Ltd. Business Overview & Revenue Model

Company Description

Medico Remedies Limited manufactures and sells allopathic pharmaceutical preparations in India. The company offers antibiotics and anti-infective drugs; beta-lactams, and penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, and anti-epileptics and antipsychotics products; antimalarial medicines; dry syrups; ointments and creams; anti-diabetics products; and syrups. It also exports its products to Kazakhstan, Kyrgyzstan, Botswana, Jamaica, and Niger. Medico Remedies Limited was incorporated in 1994 and is based in Mumbai, India.

How the Company Makes Money

Medico Remedies Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is based on the manufacturing and distribution of generic and branded formulations across different therapeutic categories. Medico Remedies earns income by supplying its products to hospitals, pharmacies, and healthcare providers. Additionally, the company has established partnerships with distributors and agents to enhance its market reach. Export sales contribute significantly to its earnings, as Medico Remedies exports its products to various international markets, benefiting from global demand for cost-effective healthcare solutions.

Medico Remedies Ltd. Financial Statement Overview

Summary

Medico Remedies Ltd. shows strong revenue growth and profitability with a healthy gross profit margin. The balance sheet is solid with prudent leverage, though there is moderate reliance on liabilities. Cash flow is positive, but capital expenditures need monitoring.

Income Statement

Medico Remedies Ltd. demonstrates strong revenue growth with a consistent increase in total revenue over the past years, indicating robust business expansion. The gross profit margin is healthy, reflecting effective cost management relative to revenue. Additionally, the net profit margin shows improvement, highlighting enhanced profitability. However, the EBIT margin appears to be less stable, suggesting potential volatility in operating efficiency, which needs attention.

Balance Sheet

The company's balance sheet shows a solid equity base with a favorable debt-to-equity ratio, indicating prudent leverage management. The return on equity is improving, showcasing effective utilization of shareholder funds. However, the equity ratio suggests a moderate reliance on liabilities, which could pose risks if not managed carefully.

Cash Flow

Medico Remedies Ltd. exhibits positive free cash flow growth, which is a positive indicator of financial health and capacity for reinvestment. The operating cash flow to net income ratio is strong, highlighting effective conversion of income into cash. However, the free cash flow to net income ratio is lower, suggesting that capital expenditures are absorbing a significant portion of free cash flow, which may impact future liquidity if not controlled.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.51B	1.51B	1.40B	1.45B	1.18B	1.22B
Gross Profit	404.17M	426.11M	355.66M	175.25M	226.30M	234.09M
EBITDA	173.91M	150.03M	135.66M	177.36M	93.34M	62.59M
Net Income	100.93M	100.93M	72.42M	82.91M	48.12M	25.90M
Balance Sheet
Total Assets	1.20B	1.20B	874.48M	961.95M	761.90M	756.21M
Cash, Cash Equivalents and Short-Term Investments	25.45M	25.45M	21.95M	15.46M	23.40M	38.86M
Total Debt	147.00M	147.00M	97.62M	80.50M	106.10M	150.53M
Total Liabilities	573.30M	573.30M	436.05M	438.24M	388.70M	431.63M
Stockholders Equity	624.69M	624.69M	438.43M	523.71M	373.20M	324.58M
Cash Flow
Free Cash Flow	0.00	17.07M	15.75M	2.04M	-11.50M	4.72M
Operating Cash Flow	0.00	48.92M	81.67M	26.83M	17.10M	26.08M
Investing Cash Flow	0.00	-34.60M	-66.03M	-27.70M	-28.60M	-751.83K
Financing Cash Flow	0.00	-5.20M	-18.17M	-4.90M	74.00M	-3.51M

Medico Remedies Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Positive. The current price of 47.99 is above the 20-day moving average (MA) of 41.49, above the 50-day MA of 40.59, and below the 200-day MA of 51.84, indicating a neutral trend. The MACD of 2.00 indicates Negative momentum. The RSI at 73.05 is Negative, neither overbought nor oversold. The STOCH value of 94.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MEDICO.

Medico Remedies Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	66 Neutral	₹4.00B	39.66	―	―	4.15%	21.74%
ALBERTDAVD	65 Neutral	₹4.45B	70.70	4.38%	0.64%	-9.14%	-91.11%
SMSLIFE	61 Neutral	₹3.46B	20.05	10.23%	0.13%	3.34%	-3.38%
LYKALABS	58 Neutral	₹3.39B	45.17	7.74%	―	19.40%	1286.88%
ZIMLAB	54 Neutral	₹3.57B	38.06	4.82%	―	-3.36%	-47.58%
BROOKS	42 Neutral	₹4.03B	313.47	-10.16%	―	10.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%